Worldwide Clinical Trials, a Kohlberg-backed global clinical research organization, is paying just under $500 million in its deal Tuesday to acquire Catalyst Clinical Research, two sources familiar tell Axios.
Why it matters: Private equity has been steadily consolidating CROs in the last year.
